Bronchial reactivity in healthy individuals undergoing long-term topical treatment with β-blockers

Archives of Ophthalmology

Volumn 123, Issue 1, 2005, Pages 35-38

  Gandolfi, Stefano A ^a   Chetta, Alfredo ^a   Cimino, Luca ^a   Mora, Paolo ^a   Sangermani, Chiara ^a   Tardini, Maria Grazia ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METHACHOLINE; TIMOLOL;

ADULT; AGED; ARGON LASER; ARTERIAL PRESSURE; ARTICLE; BRONCHUS REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART RATE; HUMAN; INTRAOCULAR HYPERTENSION; LONG TERM CARE; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; TOPICAL TREATMENT; TRABECULOPLASTY; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; BRONCHIAL HYPERREACTIVITY; BRONCHOCONSTRICTOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LONG-TERM CARE; LUNG; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; TIMOLOL; TRABECULECTOMY;

EID: 12144268001     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.1.35     Document Type: Article

References (13)

1. Zimmerman TJ. Topical ophthalmic β-blockers: a comparative review. J Ocul Pharmacol. 1993;9:373-384.
2. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology. 1980;87:447-450.
3. Schoene RB, Abuan T, Ward RL, Beasley CH. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol. 1984;97:86-92.
4. Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniack RM. The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. Am Rev Respir Dis. 1986;133:264-268.
5. Diggory P, Cassels-Brown A, Vail A, Abbey LM, Hillman JS. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet. 1995;345:1604-1606.
6. Diggory P, Cassels-Brown A, Vail A, Hillman JS. Randomised controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol. 1998;82:146-149.
7. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol. 2000;84:710-713.
8. Woolcock AJ, Anderson SD, Peat JK, et al. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis. 1991;143:1438-1443.
9. Martin RJ, Cicutto LC, Ballard RD. Factors related to the nocturnal worsening of asthma. Am Rev Respir Dis. 1990;141:33-38.
10. Hayreh SS, Podhajsky P, Zimmerman MB. β-Blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128:301-309.
11. Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91:1361-1363.
12. Hoffman BB. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Gilman AG, eds. The Pharmacological Basis of Therapeutics. 10th ed. Burr Ridge, III: McGraw-Hill Professional: 2001: 215-268.
13. Juzych MS, Zimmerman TJ. β-Blockers. In: Zimmerman TJ, ed. Textbook of Ocular Pharmacology. Philadelphia, Pa: Lippincott-Raven; 1997:261-276.